Company newsMRNA
Explain this story: Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
Moderna's stock (MRNA) has surged over 500% in 2026, significantly outperforming its rival BioNTech, primarily due to positive top-line results from its personalized cancer therapy, intismeran, in a melanoma trial. The market is now keenly awaiting detailed Phase 3 data on October 24 at the ESMO Presidential Symposium, which carries significant binary risk for the stock's future trajectory. Investors are advised to consider the potential for either validation of the rally or a sharp compression of the stock's valuation based on the upcoming data.
Other24/7 Wall St.Sector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Moderna's stock (MRNA) has surged over 500% in 2026, significantly outperforming its rival BioNTech, primarily due to positive top-line results from its personalized cancer therapy, intismeran, in a melanoma trial. The market is now keenly awaiting detailed Phase 3 data on October 24 at the ESMO Presidential Symposium, which carries significant binary risk for the stock's future trajectory. Investors are advised to consider the potential for either validation of the rally or a sharp compression of the stock's valuation based on the upcoming data.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Also mentioned:MRK
Published Sep 22, 2026, 11:17 ET · on this site +4d 14h